Literature DB >> 15095270

Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity.

Maria Debiec-Rychter1, Bartosz Wasag, Michel Stul, Ivo De Wever, Allan Van Oosterom, Anne Hagemeijer, Raf Sciot.   

Abstract

Gastrointestinal stromal tumours (GISTs) are currently defined as mesenchymal tumours of the gastrointestinal tract that express KIT receptor tyrosine kinase. However, a small subgroup of tumours that fulfil the clinical and morphological criteria for GISTs lack KIT expression. So far, the biological features of these tumours have rarely been addressed. The present study describes seven gastrointestinal stromal neoplasms that presented clinicopathological features typical of GISTs but showed absence of CD117 expression as detected by immunohistochemistry. The tumours originated from the stomach (n = 5), duodenum (n = 1), and colon (n = 1), showing histologically either predominantly epithelioid (n = 3), mixed spindled and epithelioid (n = 2), or anaplastic/spindle cell (n = 2) type features. CD34 and alpha-smooth muscle actin (alpha-SMA) positivity was present in four and three tumours, respectively. Chromosomal analysis was performed in two cases, both showing losses of chromosomes 14, 22, and 1p, which is the characteristic feature of GISTs. Dual-colour interphase fluorescence in situ hybridization (FISH) analysis, utilizing chromosome 1p-, 14-, and 22-specific probes, revealed a similar cytogenetic profile in the remaining five tumour specimens. Mutational analysis of exons 9, 11, 13, and 17 of KIT, and exons 12 and 18 of PDGFRA was performed in all cases by denaturing high-pressure liquid chromatography (DHPLC) pre-screening, followed by direct sequencing. None of the tumours showed KIT mutant isoforms. Three tumours harboured PDGFRA exon 18 activating mutations; two were Asp --> Val(842) missense substitutions and one was a DIM842-844 amino acid deletion. KIT and PKC theta (protein activated in interstitial cells of Cajal and GISTs) expression was determined by western immunoblotting of the total cell lysates from three tumour biopsies. None of these three tumours expressed KIT, while all specimens showed expression of PKC theta protein. These findings indicate that there is a subgroup of KIT-negative GISTs that exhibit the same morphological, cytogenetic, and molecular features as KIT-positive tumours. While intragenic PDGFRA activating mutations are present in some of these tumours, the oncogenic events underlying the pathogenesis of the others remain unknown. Copyright 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095270     DOI: 10.1002/path.1546

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  54 in total

Review 1.  Gastrointestinal stromal tumors: morphological, immunohistochemical and molecular changes associated with kinase inhibitor therapy.

Authors:  Mario Díaz Delgado; Alicia Hernández Amate; Sofía Pereira Gallardo; Sara Jaramillo; Juan Antonio Virizuela Echaburu; Ricardo J González-Cámpora
Journal:  Pathol Oncol Res       Date:  2011-01-29       Impact factor: 3.201

2.  NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Cristina R Antonescu; Ronald P DeMatteo; Kristen N Ganjoo; Robert G Maki; Peter W T Pisters; Chandrajit P Raut; Richard F Riedel; Scott Schuetze; Hema M Sundar; Jonathan C Trent; Jeffrey D Wayne
Journal:  J Natl Compr Canc Netw       Date:  2010-04       Impact factor: 11.908

3.  CT and MRI findings in KIT-weak or KIT-negative atypical gastrointestinal stromal tumors.

Authors:  Ukihide Tateishi; Mototaka Miyake; Tetsuo Maeda; Yasuaki Arai; Kunihiko Seki; Tadashi Hasegawa
Journal:  Eur Radiol       Date:  2006-01-06       Impact factor: 5.315

4.  The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated.

Authors:  R Penzel; S Aulmann; M Moock; M Schwarzbach; R J Rieker; G Mechtersheimer
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

Review 5.  Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach.

Authors:  Robert J Coffey; Mary Kay Washington; Christopher L Corless; Michael C Heinrich
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

6.  Mutation assay of the novel gene DOG1 in gastrointestinal stromal tumors (GISTs).

Authors:  Shigeharu Miwa; Takahiko Nakajima; Yoshihiro Murai; Yasuo Takano; Toshiro Sugiyama
Journal:  J Gastroenterol       Date:  2008-07-23       Impact factor: 7.527

7.  Esophageal mesenchymal tumors: endoscopy, pathology and immunohistochemistry.

Authors:  Xuan Zhu; Xiao-Qian Zhang; Bi-Min Li; Ping Xu; Kun-He Zhang; Jiang Chen
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

8.  Diagnostic challenges of motility disorders: optimal detection of CD117+ interstitial cells of Cajal.

Authors:  Megan M Garrity; Simon J Gibbons; Thomas C Smyrk; Jean Marie Vanderwinden; Pedro Julian Gomez-Pinilla; Anoop Nehra; Matthew Borg; Gianrico Farrugia
Journal:  Histopathology       Date:  2009-02       Impact factor: 5.087

Review 9.  A young man with primary prostatic extra-gastrointestinal stromal tumor: a rare case report and review of the literature.

Authors:  Zhi-Hong Zhang; Guo-Wei Feng; Zhi-Fei Liu; Lei Qiao; Tao Zhang; Chao Gao; Yong Xu
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

10.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Authors:  Michael C Heinrich; Kouros Owzar; Christopher L Corless; Donna Hollis; Ernest C Borden; Christopher D M Fletcher; Christopher W Ryan; Margaret von Mehren; Charles D Blanke; Cathryn Rankin; Robert S Benjamin; Vivien H Bramwell; George D Demetri; Monica M Bertagnolli; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.